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Abstract
The hexameric purine nucleoside phosphorylase from Bacillus subtilis (BsPNP233) displays great potential to produce
nucleoside analogues in industry and can be exploited in the development of new anti-tumor gene therapies. In order to
provide structural basis for enzyme and substrates rational optimization, aiming at those applications, the present work
shows a thorough and detailed structural description of the binding mode of substrates and nucleoside analogues to the
active site of the hexameric BsPNP233. Here we report the crystal structure of BsPNP233 in the apo form and in complex
with 11 ligands, including clinically relevant compounds. The crystal structure of six ligands (adenine, 29deoxyguanosine,
aciclovir, ganciclovir, 8-bromoguanosine, 6-chloroguanosine) in complex with a hexameric PNP are presented for the first
time. Our data showed that free bases adopt alternative conformations in the BsPNP233 active site and indicated that
binding of the co-substrate (29deoxy)ribose 1-phosphate might contribute for stabilizing the bases in a favorable
orientation for catalysis. The BsPNP233-adenosine complex revealed that a hydrogen bond between the 59 hydroxyl group
of adenosine and Arg43* side chain contributes for the ribosyl radical to adopt an unusual C3’-endo conformation. The
structures with 6-chloroguanosine and 8-bromoguanosine pointed out that the Cl6 and Br8 substrate modifications seem to
be detrimental for catalysis and can be explored in the design of inhibitors for hexameric PNPs from pathogens. Our data
also corroborated the competitive inhibition mechanism of hexameric PNPs by tubercidin and suggested that the acyclic
nucleoside ganciclovir is a better inhibitor for hexameric PNPs than aciclovir. Furthermore, comparative structural analyses
indicated that the replacement of Ser90 by a threonine in the B. cereus hexameric adenosine phosphorylase (Thr91) is
responsible for the lack of negative cooperativity of phosphate binding in this enzyme.
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Introduction
Purine nucleoside phosphorylases (PNPs; EC 2.4.2.1) are
versatile enzymes that catalyze the reversible phosphorolysis of
purine (29deoxy)ribonucleosides producing bases and (29deoxy)ri-
bose 1-phosphate [1]. Their key role in the purine salvage pathway
made PNPs attractive targets for drug design against several
pathogens, such as Mycobacterium tuberculosis [2,3], Plasmodium
falciparum [4–7], Trichomonas vaginalis [8–10] and Schistosoma mansoni
[11,12], which lacks the de novo pathway for purine nucleotides
synthesis. Due to their catalytic function, PNPs have also been
investigated for the synthesis of nucleoside analogues (NAs) [13]
and the activation of prodrugs in anti-cancer gene therapies [14].
NAs can be used in the treatment of a range of human viral
infections, such as those caused by HIV, herpesvirus and hepatitis
B/C virus [15–19]. They are among the first cytotoxic molecules
to be used in the treatment of cancer [20] and have been studied
as potential drugs against tuberculosis [21,22], malaria [7,23],
trichomoniasis [24] and schistosomiasis [25]. The chemical
synthesis of these compounds is generally a costly multistep
process that includes several protection and deprotection stages
[13,26]. This has encouraged the development of new methods for
the synthesis of NAs using PNPs and other enzymes as biocatalysts
[13,27,28]. The main advantages of this approach are the higher
stereospecificity, regioselectivity and efficiency of enzymes, whose
employment usually dispenses group protection and purification
steps, optimizing the process [13].
The differences in substrate specificity regarding trimeric and
hexameric PNPs have allowed the development of suicide gene
therapies strategies against solid tumors [14,29]. Trimeric PNPs
are mainly found in mammalian species and are specific for
guanine and hypoxanthine (29-deoxy)ribonucleosides whereas
hexameric PNPs are prevalent in bacteria and accept adenine as
well as guanine and hypoxanthine (29-deoxy)ribonucleosides as
substrates [1]. Thus, nontoxic adenosine analogues, which are
poor substrates for human PNP, can be cleaved to cytotoxic bases
specifically in tumor cells transfected with the bacterial hexameric
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PNP gene [14]. Main advances in this field have been achieved
with the E. coli PNP [30–33].
In this context, the aim of the present work was to shed light on
how a diverse set of substrate modifications affects its binding and
catalysis by hexameric PNPs using a structural approach. For this
purpose, we choose the hexameric PNP (BsPNP233) from the
model specie Bacillus subtilis, which displays great biotechnological
potential to produce NAs, including the antiviral drug ribavirin
[34]. We have solved the crystal structure of BsPNP233 in the apo
form and in complex with 11 ligands comprising sulfate, bases,
natural nucleosides and NAs, including clinically relevant com-
pounds. The crystal structure of six ligands (adenine, 29deox-
yguanosine, aciclovir, ganciclovir, 8-bromoguanosine, 6-chloro-
guanosine) in complex with a hexameric PNP are presented for the
first time.
Besides providing a broad structural basis for studies aiming at
the rational design of BsPNP233 and its homologues for
biotechnological applications, this work also bring new insights
into the distinct kinetic models for phosphate binding in hexameric
PNPs. Furthermore, the structural information showed here may
also be instrumental for the development of new inhibitors against
hexameric PNPs from pathogens such as Plasmodium falciparum and
Trichomonas vaginalis [5,6,8,9] and for the combined design of both
hexameric PNPs and prodrugs to improve specificity and
efficiency of anti-cancer PNP gene therapies [14].
Materials and Methods
Chemicals
Adenine (Ade), adenosine (Ado), 2-fluoradenosine (F-Ado),
tubercidin (TBN), 29-deoxyguanosine (dGuo), hypoxanthine
(Hyp), ganciclovir (GCV), aciclovir (ACV), 8-bromoguanosine
(Br-Guo) and 6-chloroguanosine (Cl-Guo) were all purchased from
Sigma-Aldrich.
Expression and Purification of Recombinant BsPNP233
BsPNP233 was expressed in E. coli cells and purified by
immobilized metal affinity and size-exclusion chromatographies as
described in [35]. The protein concentration was determined by
absorption spectroscopy at 280 nm using the theoretical molar
extinction coefficient of 16 515 M21cm21 calculated by the
program ProtParam [36].
Crystallization
BsPNP233 at 11 mg/ml in 20 mM Tris–HCl pH 7.0, 50 mM
NaCl and 1 mM DTT was crystallized by sitting-drop vapor-
diffusion technique according to conditions previously described
[35]. The crystals belong to the space groups P321, P6322, P212121
and H32 with one, two or six monomers per asymmetric unit
depending on symmetry and cell dimensions.
Preparation of BsPNP233-ligand Complexes
The protein-ligand complexes were prepared by adding 0.1 ml
of 50 mM ligand, dissolved in DMSO, to 1 ml crystallization drops
at least 12 h prior to data collection. The ligands used were
nucleosides, purine bases and NAs (Table S1). This procedure was
performed in drops containing BsPNP233 crystals grown in 0.1 M
sodium acetate pH 4.6, 3.2 M sodium chloride, 5% (v/v) glycerol
at 291 K.
X-ray Data Collection and Processing
X-ray diffraction experiments were performed on the W01B-
MX2 beamline at the Brazilian Synchrotron Light Laboratory
(Campinas, Brazil). The data collection was carried out using
crystals soaked in a cryoprotectant solution composed by the
mother liquor and 20% (v/v) glycerol and flash-cooled in a
nitrogen-gas stream at 100 K. The radiation wavelength was set to
1.458 A˚ and a MAR Mosaic 225 mm CCD detector was used to
record the X-ray diffraction data. Data were indexed, integrated
and scaled using the HKL-2000 suite [37] or the programs
MOSFLM [38] and SCALA [39] from the CCP4 package [40].
Data processing statistics are summarized in Table S1.
Structure Determination and Refinement
The structures were solved by molecular replacement using the
programs MOLREP [41] or PHASER [42], both from the CCP4
suite [40]. The first BsPNP233 structure was determined using the
atomic coordinates of B. anthracis PNP (PDB code 1XE3) [43] as a
search model. The subsequent BsPNP233 structures were solved
using the atomic coordinates of BsPNP233 solved at 1.7 A˚
resolution (BsPNP233-GCV dataset, Table S1) as template.
Refinement was carried out using the programs REFMAC5 [44]
and COOT [45]. After 20 cycles of rigid body refinement in
REFMAC5 [44], the models were refined alternating cycles of
restrained isotropic refinement in REFMAC5 [44] and manual
rebuilding and real space refinement in COOT [45]. Water
molecules were added after refinement of the protein model at
chemically reasonable places using COOT [45]. Subsequently, the
ligands were added to the model and refined as described above
using library descriptions generated by the program SKETCHER
from the CCP4 suite [40]. The intensity based twin refinement of
REFMAC5 was applied to refine the structures of BsPNP233 in
complex with adenosine, 2-fluoradenosine and adenine. The
majority of models for the BsPNP233 protein included all but the
first and last residues (1 and 233). In the electron density map of
the crystal structure solved in the space group P212121 the residue
1 and additional eight residues from the N-terminal his-tag were
clearly defined and added to the model. Ramachandran analysis
carried out by Molprobity [46] showed that all residues from all
models are found in allowed regions (except Gly121 of the
BsPNP233-Ade structure, chain B). Refinement statistics are
detailed in Table S1. Weighted 2Fo-Fc maps (2mFo-DFcalc) of
ligands as well as a table of interactions between ligands and
protein residues are presented in the supplementary material
(Figure S1, Table S2). The atomic coordinates and structure
factors of form I (4D8V), form II (4D8X), form III (4D8Y), form
IV (4D98) and the complexes of BsPNP233 with Hyp (4DAB), Ade
(4DAO), Ado (4D9H), dGuo (4DA0), F-Ado (4DAN), Cl-
Guo(4DAE), Br-Guo (4DA8), TBN (4DAR), GCV (4DA6) and
ACV (4DA7) have been deposited in the Protein Data Bank,
Research Collaboratory for Structural Bioinformatics, Rutgers
University, New Brunswick, NJ (http://www.rcsb.org/).
Figure Preparation
The figures of structures were prepared using PyMOL [47].
Structural Alignment
All structural comparisons were performed using the SSM
algorithm [48] available at the program COOT [45] or at the
PDBeFold server [49].
Results and Discussion
BsPNP233 Conserves the Quaternary Structure and
Topology of Hexameric PNPs
The crystal structure of BsPNP233 confirmed that it is a
homohexamer with D3 symmetry as observed for other hexameric
PNPs (Figure 1A) [50,51]. It was solved by X-ray crystallography
Structural Insights into Hexameric PNPs
PLOS ONE | www.plosone.org 2 September 2012 | Volume 7 | Issue 9 | e44282
in four distinct space groups (P321, P212121, P6322 and H32). The
crystal contacts are similar in the crystal structures solved in P321,
P212121 and P6322 but differ in the H32 space group. In the later,
we observed additional crystallographic interfaces, resulting from a
more compact crystal packing with a lower solvent content (41%)
than crystals belonging to other space groups (,56%) (Figure S2)
[35].
The BsPNP233 subunits surround a central axis and alternate in
an up/down fashion forming a disc-shaped structure with six
active sites: three located at the top face and other three at the
bottom face. Analogously to other hexameric PNPs, BsPNP233 is
a trimer of dimers where each subunit interacts with the adjacent
subunits forming two interfaces: the catalytic, which contains the
active site, and the inter-dimeric, involved in hexamer stabilization
(Figure 1A). The inter-dimeric interface is larger than the catalytic
interface and both are mainly maintained by hydrophobic
interactions. In the ligand-free crystal structure (form II), the
inter-dimeric and the catalytic interface areas are 1711 and
1554 A˚2, respectively.
The BsPNP233 subunit conserves the E. coli hexameric PNP
(EcPNP) subunit topology with few exceptions. Its central mixed b-
sheet lacks the short b10 strand observed in EcPNP [50] and is
surrounded by eight (instead of seven) a-helices (Figure 1B). The
extra 5-residues a-helix connects the strands b2 and b3 and is not
labeled to preserves the Mao and colleagues notation [50].
BsPNP233 and EcPNP subunits share sequence identity of 58%
(PDB code 1ECP, [50]) and superpose with a r.m.s.d of 0.93 A˚ for
231 Ca atoms aligned (Figure S3). Structural alignment of
BsPNP233 subunit with hexameric PNPs subunits from other
Bacillus species resulted in a r.m.s.d of 0.80 A˚ - 0.94 A˚ for 231 Ca
atoms aligned and an average sequence identity of 71% (Figure
S3).
Analysis of the B-factor distribution in the apo BsPNP233
crystal structure shows that the loop connecting b9 and a7 as well
as the N-terminal portion of a7 present the highest B-factor values,
highlighting its intrinsic flexibility. As this region surround the
active site, its flexibility may be important for catalysis (Figure 1C).
Free Purine Bases Adopt Alternative Conformations in
the Active Site
The crystal structures of BsPNP233 in complex with hypoxan-
thine (Hyp) and adenine (Ade) showed that the purine-binding site
consists of residues Cys91, Gly92, Phe159, Val177 and Met179.
Hydrophobic interactions are predominant in the stabilization of
both ligands (Figure 2A).
The BsPNP233-Ade binary complex was solved with
(BsPNP233-Ade-SO4) or without (BsPNP233-Ade) sulfate ion
and represent the first of their kind to be reported for hexameric
PNPs. Two subunits were observed in the asymmetric unit of both
crystal structures and all of them exhibited clear density for the
ligand in the active site (Figure S1).
Superposition of BsPNP233-Ade and BsPNP233-Ade-SO4
complexes showed a preferential orientation of Ade in the base-
binding site, except in one case where it is rotated by 49u around
an axis perpendicular to the base plane (Figure 2B). This
alternative orientation is not followed by significant conforma-
tional changes in the active-site residues (Figure 2B); however, it
alters the solvation of the active-site pocket. In the alternative
orientation, a crystallographic water molecule in the ribose-
binding site is absent. This solvent molecule mediates a hydrogen
bond between the AdeN9 atom and the carbonyl group of Ser90 in
the presence of sulfate ion (Figure 2B).
Interestingly, the Hyp adopts an orientation similar to the
alternative conformation of Ade (Figure 2C). In this case, a
glycerol molecule is located in the ribose-binding site and seems to
induce the displacement of Hyp, avoiding a steric clash with the
HypN9 atom. This observation, along with those described above,
suggests that binding of the co-substrate ribose-1-phoshate might
contribute for stabilizing the base in the favorable orientation for
catalysis.
The Hydrogen Bond between the 59 Hydroxyl Group of
Ado and Arg43* Side Chain Contributes for a Ribosyl C39-
endo Conformation
The base moiety of adenosine (Ado) binds to the BsPNP233
active site in a very similar fashion to that seen in homologous
PNPs (Figure 3). However, the ribosyl group adopts a C39-endo
form instead of the C49-endo or O49-exo conformations usually
observed in Ado complexes with hexameric PNPs (PDB codes
Figure 1. Overall structure of BsPNP233. A. Cartoon representa-
tion of the hexamer BsPNP233 with adenine (red spheres) bound in the
active site. Solid and dashed grey arrows indicate the inter-dimeric and
catalytic interfaces, respectively. B. Cartoon representation of BsPNP233
protomer in complex with adenosine (green stick). Loops, a-helices and
b-strands are shown in yellow, blue and pink. The a-helices and b-
strands were numbered according to the Mao and colleagues notation
[50]. C. BsPNP233 protomer colored by B-factors from dark blue (lowest)
to red (highest). Adenosine is represented by a black stick.
doi:10.1371/journal.pone.0044282.g001
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3UAW, [52]; 1ODI, [53]; 1PK7, [54]; 3U40, [55]; 1Z37, [51];
1VHW, [56]) (Figure 3). This unusual conformation may be
explained by a hydrogen bond between the 59 hydroxyl group of
Ado and Arg43* side chain (residues from the adjacent subunit are
designated by an asterisk) not observed in other Ado complexes
(Figure 3). Typically, the 59-OH group of Ado is found interacting
with one or two water molecules not observed in BsPNP233-Ado
complex, suggesting that the hydration of the active site may
influence the ribosyl conformation.
In sulfate/phosphate free complexes of hexameric PNPs with
Ado, an O49–exo conformation is usually found. However, in all
complexes where the phosphate-binding site is occupied by a
sulfate or phosphate, the ribosyl group shows a C49–endo
conformation, except for the Thermus thermophilus (TtPNP)-Ado
complex (PDB code 1ODI, [53]). Since the side chain of Arg43*
participates in phosphate binding, the presence of this co-substrate
and the hydration of the active site probably prevent the
interaction between Ado 59-OH group and Arg43* side chain
observed in BsPNP233-Ado complex favoring the ribose to adopt
a C49–endo conformation.
29-deoxyguanosine Binding Mode Resembles to that
Observed for Adenosine
In the BsPNP233-(29-deoxyguanosine) complex structure, the
base of 29-deoxyguanosine (dGuo) binds to the active site in a
similar manner to that observed for Ado (Figure 4). Neither the
extra amino group at position 2 nor the carbonyl group at position
6 was observed making hydrogen bonds with the protein residues.
A hydrogen bond between dGuoN7 and Ser202Oc atoms slightly
rotates the base and brings the residue Ser202 closer to the
substrate (Figure 4B). The lack of the 29-OH group in dGuo is
counterbalanced by extra hydrophobic interactions between
dGuoC29 and Glu178 carbon atoms (Figure 4A). Comparisons
between BsPNP233-dGuo and T. vaginalis PNP (TvPNP)-(29-
deoxyinosine) complexes showed that the deoxyribosyl group of
both ligands conserves the binding mode, whereas the base
assumes a little different orientation induced by the dGuoN7-
Ser202Oc hydrogen bond exclusively observed in BsPNP233-dGuo
complex (Figure 4C).
BsPNP233 can be Explored as an Alternative in Gene
Therapy Approaches using 2-Fluoradenosine as Prodrug
The compound 2-fluoradenosine (F-Ado) is an adenosine
analogue which liberates the toxic metabolite 2-fluoradenine
when cleaved. Its deoxy form has been studied as a prodrug in an
anti-tumor gene therapy approach based on a modified human
PNP [57]. The crystal structure of BsPNP233-(F-Ado) complex
had two BsPNP233 subunits per asymmetric unit and both
presented clear electronic density for the ligand (Figure S1). In the
two independent active sites, F-Ado was found in the same
orientation, similar to that of Ado (Figure 4E). The extra fluorine
atom at position 2 is allocated in a hydrophobic micro-
Figure 2. Comparison of free bases bound to the BsPNP233 active site. A. Structural comparison of a representative BsPNP233-Ade complex
(purple carbon atoms) with the BsPNP233-Hyp complex (grey carbon atoms). B. The structure of the four BsPNP233-Ade complexes solved
independently are superimposed. The sulfate-free Ade-complexes are colored in purple (chain A) and pink (chain B) whereas the two independent
complexes solved with sulfate bound (dataset I) are colored in orange (chain A) and blue (chain B). C. The structure of the Ade-complex where Ade
presents an alternative conformation (carbon atoms in orange) is superimposed in the structure of Hyp-complex (carbon atoms in grey). The surface
of the glycerol molecule present at the Hyp-complex is shown to evidence the influence of this molecule in the position and orientation of Hyp in the
active site. The hydrogen bonds are shown as dashed lines.
doi:10.1371/journal.pone.0044282.g002
Figure 3. The different conformations of Ado ribosyl radical.
Structural superposition of BsPNP233-Ado (magenta carbon atoms),
B. cereus adenosine phosphorylase (BcAdoP)-Ado-SO4 (green carbon
atoms, PDB code 3UAW [52]) and Entamoeba histolytica PNP-Ado (cyan
carbon atoms, PDB code 3U40 [55]) complexes. The different puckers
adopted by the ribose moiety of adenosine are labeled and the
hydrogen bonds involving the 59-OH group of Ado in each complex are
represented by dashed lines. The sugar puckers were assigned by the
pucker.py script of PyMOL [47].
doi:10.1371/journal.pone.0044282.g003
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environment consisting of Ala156, Phe159, Val177 and Met179
(Figure 4D). This motif is fully conserved in EcPNP, which has
been tested in anti-tumor gene therapy by activating produgs like
F-ado [30].
Two hydrogen bonds (N6-Asp203Od and N7-Ser202Oc) observed
in BsPNP233-F-Ado complex, but not in BsPNP233-Ado com-
plex, contribute for subtle changes in nucleoside position and base
orientation (Figure 4E). The F-Ado ribosyl moiety adopts the
catalytically favorable C49-endo conformation supported by tight
hydrogen bonds of nucleoside sugar hydroxyl groups with His4*,
Arg87 and Glu180 side chains (Figure 4E). Structural comparisons
among BsPNP233-F-Ado, TvPNP-F-Ado (PDB code 1Z35) and
EcPNP-F-Ado (PDB code 1PK9) complexes showed a similar
binding mode. However, the presence of phosphate in the EcPNP-
(F-Ado) complex displaces by about 0.5 A˚ the ribosyl moiety,
disrupts the N7-Ser202Oc hydrogen bond and leads the N7 atom
closer to the Asp203 side chain, favoring the catalysis (Figure 4F).
Since F-Ado binds to the BsPNP233 active site in a manner
similar to that of the natural substrate Ado, placing the F2 atom in
a hydrophobic pocket conserved in EcPNP, our structural data
indicate that, as well as EcPNP [54], BsPNP233 is able to convert
2-fluoradenosine in the cytotoxic 2-fluoradenine. Thus, we
concluded that BsPNP233 can be explored as an alternative in
the development of anti-tumors gene therapy approaches using
this prodrug or the less toxic 2-fluoro-29-deoxyadenosine [57].
The Cl6 Substituent of 6-chloroguanosine Induces a
Ribose C39-exo Conformation and May Prevent Catalysis
The NA 6-chloroguanosine (Cl-Guo) can be used for the
synthesis of 2-amino-6-chloro-9-(2,3-dideoxy-3-fluoro-beta-D-ery-
thro-pentofuranosyl)purine, a compound with anti-HBV effects
[58]. In addition, the free base 6-chloroguanine is an inhibitor of
the trimeric PNP from Schistosoma mansoni [59]. Here we report the
first crystal structure of a PNP in complex with Cl-Guo.
The molecule Cl-Guo displays a similar binding mode to that
observed for dGuo (Figure 5A). However, as the chlorine van der
Waals radius is larger than that of oxygen, the Cl6 substituent
pushes the base in the direction of the ribosyl moiety to avoid steric
clashes with Gly92Ca, Val205Cc2, and Asp203Od1 atoms. This base
displacement induces the ribosyl group to adopt an unusual C39-
exo conformation.
The C39-exo pucker was already observed in the nucleoside 9-b-
D-xylofuranosyladenine bound to EcPNP (PDB code 1PR6, [54])
and it is considered incompatible with the sugar conformation
required for PNP catalysis [54]. Moreover, structural comparisons
with the EcPNP-Ado-PO4 complex (PDB code 1PK7, [54])
showed that the chlorine atom may prevent the Asp203 side chain
to approach to the N7 atom to donate a proton during catalysis
(Figure 5B). Thus, these findings suggest that Cl-Guo as well as
other NAs with 6-substituents heavier than chlorine cannot be
cleaved by BsPNP233 and other hexameric PNPs.
Figure 4. The binding mode of 29 deoxyguanosine and 2-fluoradenosine. A. Representation of the BsPNP233 residues that interact with
dGuo showing as spheres the atoms involved in hydrophobic interactions with dGuo C29 atom. B. Structural alignment between the dGuo-complex
(carbon atoms in orange) and the Ado-complex (carbon atoms in grey). C The structure of dGuo-complex and TvPNP-(29-deoxyinosine) complex
(carbon atoms in green, PDB code 1Z39, [51]) are superimposed. D. Representation of F-Ado complex showing the residues involved in van der Waals
interactions with F2 atom (light blue sphere). E. Structural comparison of F-Ado complex (carbon atoms in yellow) with the Ado-complex (carbon
atoms in grey). F. The structures of F-Ado complex, EcPNP-F-Ado-PO4 complex (carbon atoms in pink, PDB code 1PK9 [54]) and TvPNP-F-Ado complex
(carbon atoms in green, PDB code 1Z35, [51]) are superimposed. In all panels hydrogen bonds are represented by dashed lines and color coded
according to their respective structures.
doi:10.1371/journal.pone.0044282.g004
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The Br8 Substituent Displaces Ser90 Away from the
Phosphate Binding Site and Might be Detrimental for
Catalysis
The 8-bromoguanosine (Br-Guo) is a ‘‘poor substrate’’ of the
trimeric PNP from calf spleen [60]. Its first crystallographic
portrayal in complex with a protein is described here. The
addition of a bromine radical at the C8 atom of guanosine results
in the formation of a halogen bond between Br8 and Ser90Oc
atoms, which implicates in both positional and rotational
displacement of the base by 0.3 A˚ and 7u, respectively
(Figure 5C). The ribosyl moiety of Br-Guo presents a typical
C49–endo conformation and binds to the active site in a very similar
fashion to that seen for 29deoxyguanosine (Figure 5C).
In BsPNP233-(Br-Guo) complex, the side chain of the catalytic
residue Asp203 is facing the O6 and N7 atoms of Br-Guo and the
Ser90 side chain is pushed away from the active site in order to
accommodate the bromine atom (Figure 5C). In hexameric PNPs,
the hydroxyl group of Ser90 participates in the coordination of
phosphate [61]. The position that it assumes in BsPNP233-sulfate
and EcPNP-Ado-PO4 complexes (PDB code 1PK7 [54]) is
incompatible with the presence of Br8 atom because of steric
hindrance (Figure 5C). Thus, the bromine radical probably
prevents the phosphate-Ser90 interaction being detrimental for
binding and correct orientation of phosphate.
Site-directed mutations of human PNP phosphate binding site
leads to a decrease in catalytic efficiency ranging from 25- to 185-
fold [62]. Likewise, impairment of any phosphate interaction in
the hexameric PNP active site may reduce the catalytic activity. As
Br-Guo probably prevents the phosphate-Ser90 interaction it
might be a ‘‘poor substrate’’ or even an inhibitor of BsPNP233 and
other hexameric PNPs as well.
This interpretation cannot be applied for trimeric PNPs because
Ser90 is not structurally conserved in trimeric PNPs. However,
structural comparisons between BsPNP233-(Br-Guo) and human
PNP in complex with guanosine and sulfate (PDB code 1RFG,
[63]) indicate that Br-Guo is probably a ‘‘poor substrate’’ for
trimeric PNPs because of steric hindrance involving the bromine
and the side chain of Thr242, which would hinder the displacement
of the N7 atom towards Asn243 side chain for stabilization of the
transition state [64] (Figure 5D).
Corroboration of the Competitive Inhibition Mechanism
of Hexameric PNP by Tubercidin
Tubercidin (7-deazaadenosine) is an adenosine analogue which
presents antiviral, antischistosomal and antifungal properties as
well as antitumor activity [65–68]. Furthermore, tubercidin and
other 7-deazapurine nucleosides are inhibitors of EcPNP [69,70].
TBN presented an interaction mode very similar to that seen for
the natural substrate adenosine (Figure 6). Slightly differences were
observed in its ribosyl moiety that assumed an O49–exo pucker
instead of the C39-exo conformation of Ado in complex with
BsPNP233 (Figure 6). The C7 substituent in TBN makes
hydrophobic and van der Waals interactions with residues Cys91
and Ser202. The ribosyl moiety is stabilized by a conserved
network of hydrogen bonds involving His4*, Glu180 and Arg87 side
chains and by hydrophobic interactions with Glu178 (Ca and Cb
atoms) and Met179Cc atom (Figure 6). Our structural data
corroborate the competitive inhibition mechanism of hexameric
PNP by TBN defined by in vitro studies [69]. The substitution of N7
by a carbon prevents the protonation step of the N7 atom required
for catalysis [70], making TBN a non-cleavable adenosine
analogue by EcPNP and probably by other PNPs.
Figure 5. The influence of Cl6 and Br8 modifications in catalysis
and nucleoside binding. A. Structural alignment of Cl-Guo complex
(pink carbon atoms) and dGuo complex (cyan carbon atoms). Spheres
represent the van der Waals radius of Cl6, Gly92Ca, Asp203Od1 and
Val205Cc2 atoms. B. Superposition of Cl-Guo complex and EcPNP-Ado-
PO4 complex (yellow carbon atoms, PDB code 1PK7 [54]). Spheres
represent the van der Waals radius of Cl6 and EcPNP Asp204Od1 atoms to
highlight the steric conflict imposed by the Cl6 atom. C. The Br-Guo
complex (carbon atoms in green), dGuo complex (carbon atoms in
orange) and sulfate complex (carbon atoms in magenta, form IV, chain
B) structures are superimposed. The sphere represents the van der
Waals radius of Br8 and the dashed lines represent hydrogen bonds
colored according to the respective structures. D. Structural comparison
of Br-Guo complex and the trimeric HsPNP-Guo-SO4 complex (purple
carbon atoms, PDB code 1RFG, [63]). The spheres represent the van der
Waals radius of Br8 and HsPNP Thr242Oc1 atoms. The dashed circle has
the same radius of Br8 and indicates the steric clash that would occur if
BrGuo was placed at the Guo position in the HsPNP active site.
doi:10.1371/journal.pone.0044282.g005
Figure 6. The binding mode of tubercidin. Structural comparison
between the BsPNP233-TBN (carbon atoms in green) and BsPNP233-
Ado (carbon atoms in grey) complexes. Dashed lines indicate hydrogen
bonds and are colored according to their respective complexes.
doi:10.1371/journal.pone.0044282.g006
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Ganciclovir Inhibits Both Trimeric and Hexameric PNPs
Ganciclovir (GCV) is an acyclic NA used to treat cytomegalo-
virus infections [17]. It is also used together with herpes simplex
virus thymidine kinase in a suicide gene therapy system that has
been studied for the treatment of hepatocellular carcinoma [71].
GCV is an inhibitor of the human PNP (trimeric) [72] and
probably has inhibitory effects on hexameric PNPs as well. Our
structural data support this hypothesis revealing that GCV binds
to the nucleoside binding site of BsPNP233 (Figure 7).
The guanine moiety of GCV conserves the position observed
for the 29-deoxyguanosine base but it is rotated by about 10u to
accommodate the acyclic chain in the ribose-binding site
(Figure 7A–B). A water molecule mediates hydrogen bonds
between the ligand O6 atom and the side chains of Ser202 and
Asp203. The N7 atom interacts with Ser202Oc and Gly92N atoms,
and the base is stabilized by hydrophobic contacts with Ser90,
Cys91, Ser202 and Phe159 (Figure 7A).
Interestingly, the three oxygens of the acyclic radical occupy
similar positions to those observed for the three oxygens of dGuo
ribosyl group, mimetizing its binding mode (Figure 7B). From the
three hydrogen bonds observed for dGuo ribosyl moiety, the GCV
acyclic radical conserves two, involving the His4* and Glu180 side
chains. Moreover, the C49 atom of the GCV acyclic moiety
preserves the hydrophobic interactions with Met179Cb and
Met179Cc atoms performed by the dGuo C39 atom (Figure 7B).
Therefore our data indicate that GCV is also a competitive
inhibitor for hexameric PNPs.
Aciclovir Acyclic Chain Adopts Two Conformations in the
BsPNP233 Ribosyl Binding Site
Aciclovir (ACV) is an antiviral drug used to treat herpes virus
infections [73] and has modest inhibitory effects on human PNP
[74]. Here, we present for the first time the crystal structure of a
hexameric PNP with ACV. This structure revealed differences in
the aciclovir binding mode, which can be explored for drug design
targeting hexameric PNPs from pathogens such as P. falciparum [6]
and T. vaginalis [8].
Aciclovir binds to the BsPNP233 nucleoside binding site and is
stabilized by hydrophobic interactions and a hydrogen-bonding
network mediated by solvent molecules (Figure 7C–D). Interest-
ingly, the acyclic tail assumes two alternative conformations that,
seen simultaneously, resemble the conformation observed for the
ganciclovir acyclic radical (Figure 7C–E). In one of these
conformations, the 39 hydroxyl group of ACV is attached to the
carboxyl group of Glu180 side chain while the carbon atoms make
hydrophobic contacts with the main chain of Glu178 and with the
Met179Cb and Met179Cc atoms (Figure 7C). A phosphate ion,
modeled with half occupancy based on difference maps, also
makes a hydrogen bond with the ligand 39 hydroxyl group
(Figure 7C). The other conformation is stabilized by a hydrogen
bond between the 39-OH group of ACV and the His4* side chain
(Figure 7D).
The ACV guanine moiety assumes a different position and
orientation from that observed for GCV (Figure 7E), getting closer
to the Phe159 side chain. The main chain of Cys91 and the side
chain of Val177 also contribute with hydrophobic interactions to
the base (Figure 7C–D). The O6 atom makes water mediated
hydrogen bonds with the Asp203 side chain and with the Phe159
carbonyl oxygen (Figure 7C and D). The same is observed for N1
and N2 atoms, which interact through a water molecule with the
Gln158 carbonyl oxygen; for N7 atom, which makes water
mediated hydrogen bonds with Asp203 side chain, and; for N9
atom, whose interaction with both Ser90 and Ser202 hydroxyl
groups is also mediated by a solvent molecule (Figure 7C–D).
Structural comparison between BsPNP233-ACV and human
PNP (HsPNP)-ACV (PDB code 1PWY, [74]) complexes showed
differences in the binding mode. In the HsPNP-ACV complex, the
base N1, N2, N7 and O6 atoms interact directly with active-site
residues through hydrogen bonds. In addition, the acyclic chain
adopts a different conformation, which is stabilized by hydropho-
bic interactions with Phe200 side chain and Ala116/Ala117 main
chains (Figure 7F). To investigate if differences in the interaction
mode of aciclovir with BsPNP233 and HsPNP may result in
different binding affinities, we estimated the strength of protein–
ligand interactions using the rerank score function of MOLEGRO
[75]. According to this analysis, ACV presented similar predicted
binding affinities in both complexes, which was slightly higher
(lower rerank score value) for the BsPNP233 complex (Table S3).
The same analysis was performed for GCV whose predicted
binding affinity was considerable higher than that observed for
ACV (Table S3). This result indicates that GCV is a better
inhibitor for hexameric PNPs than ACV.
Structural Basis of Distinct Kinetic Models for Phosphate
Binding in Hexameric PNPs
The asymmetric unit of the BsPNP233 crystal structure
belonging to the H32 space group presented a catalytic dimer
whose protomers adopt an open and a closed conformation,
respectively (Figure 8A). The electron density map clearly showed
a tetrahedral molecule in the active site of both subunits (Figure
S1). As the crystallization condition was phosphate free and
contained high concentrations of ammonium sulfate, we modeled
sulfate ions in both sites.
The open and closed conformations of BsPNP233-sulfate
complex were already observed in EcPNP-sulfate/phosphate
structures and have been associated with two dissociation
constants that characterize phosphate binding to EcPNP [61,76].
The closed conformation is defined by a disruption of helix a7 and
subsequent displacement of its N-terminal portion and the
precedent loop towards the active site (Figure 8A). This
conformation seems to be triggered by the interaction of Arg24
side chain with phosphate and results in an approximation of
Arg216 to the catalytic residue Asp203 (Figure 8A) [61]. As
BsPNP233 protomers are able to adopt open and closed
conformations like EcPNP subunits, this suggests that the negative
cooperativity of phosphate binding demonstrated for EcPNP [61]
is also applied for BsPNP233.
Comparison between BsPNP233-sulfate and Bacillus cereus
adenosine phosphorylase (BcAdoP)-sulfate complexes (PDB codes
3UAV, 3UAW, 3UAX, 3UAY, 3UAZ, [52]) showed that BcAdoP
assumes an intermediate conformation where only the first turn of
helix a7 is disrupted (Figure 8A). In the BcAdoP-sulfate complex
structure (PDB code 3UAW, [52]), Arg217 (corresponding to
BsPNP233-Arg216) points to the active site but it is not able to
approach Asp204 (BsPNP233-Asp203) such as BsPNP233-Arg216
(Figure 8A).
The apparent inability of BcAdoP to adopt the closed
conformation seems to be caused by a steric hindrance imposed
by Thr91 to the conformational change that Phe221 (BsPNP233-
Phe220) undergoes for the closed conformation being achieved
(Figure 8B). In BsPNP233 and EcPNP this threonine residue is
replaced by a serine, which allows Phe220 side chain to adopt the
rotamer observed in the closed conformation (Figure 8C). These
analyses suggest that the negative cooperativity model of
phosphate binding displayed by EcPNP cannot be applied for
BcAdoP, as BcAdoP apparently presents only one conformational
state. This hypothesis is supported by functional studies, which
showed that BcAdoP obeys Michaelis–Menten kinetics [77].
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Figure 7. The binding mode of acyclic nucleosides. A. Stick representation of GCV bound in the BsPNP233 active site. B. Structural comparison
of GCV-complex (blue carbon atoms) with dGuo-complex (orange carbon atoms). C and D show the stick representation of the two conformations of
ACV (ACV1 and ACV2) bound to the BsPNP233 active site. E. The structures of GCV-complex (grey) and ACV1,2-complex (green carbon atoms) are
superimposed. F. Structural alignment of ACV1,2-complex with HsPNP-ACV complex (pink carbon atoms, PDB code 1PWY [74]). In all panels dashed
lines indicate hydrogen bonds and are color coded according to their respective complexes.
doi:10.1371/journal.pone.0044282.g007
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A previous work reported that BsPNP233 is specific for 6-
aminopurine nucleosides [78]. However, Xie and coworkers [34]
recently showed that BsPNP233 (named PNP702) exhibits a broad
substrate specificity and present comparable activity towards both
guanosine (6-oxopurine nucleoside) and adenosine (6-aminopurine
nucleoside). Our structural data is in agreement with Xie and
coworkers data indicating that BsPNP233 conserves the same
catalytic mechanism proposed for EcPNP [76], where catalysis
occurs in the closed conformation (Figure 8A).
Conclusion
This report provided a broad description of how the hexameric
PNP from B. subtilis interacts with natural substrates and the
impact of modifications in such substrates on binding and catalysis.
The structural analysis reported here can be instrumental for
studies aiming to optimize BsPNP233 or other hexameric PNPs
for biotechnological applications such as industrial synthesis of
nucleoside analogues or gene therapy against solid tumors. An
initiative of this sort has been taken for E. coli PNP to optimize the
cleavage of the prodrug Me(talo)-MeP-R with great success [29].
The crystal structure of six ligands (adenine, 29deoxyguanosine,
aciclovir, ganciclovir, 8-bromoguanosine and 6-chloroguanosine)
in complex with a hexameric PNP are presented for the first time.
The information extracted from these structures can be extended
to homologous hexameric PNPs to help the development of new
inhibitors against pathogens such as T. vaginalis [8] and P. falci-
parum [6] as well as new prodrugs for gene therapies against tumors
[30,79].
In addition, our results and comparative analyses shed light on
distinct kinetic models for phosphate binding in hexameric PNPs.
According to our model the substitution of the conserved residue
Ser90 by a threonine disrupts the open/close mechanism of
hexameric PNPs subunits, which results in the loss of the negative
cooperativity of phosphate binding.
Supporting Information
Figure S1 Weighted 2Fo-Fc map (2mFo-DFcalc) of the
ligands (ball and stick) bound to the BsPNP233 active
site. A. Ade-complex (chain A). B. Ade-SO4 complex, evidencing
only Ade (form I, chain A). C. Hyp-complex. D. Ado-complex
(chain A). E. F-Ado complex (chain A). F. dGuo complex. G. Cl-
Guo complex. H. Br-Guo complex. I. TBN complex. J. GCV
complex. K. ACV complex. L. SO4 complex (form IV, chain A).
(TIF)
Figure S2 Crystallographic interfaces (dark grey) ob-
served at the crystal structures solved at space groups
P321, P212121, P6322 (A) and at H32 space group (B).
(TIF)
Figure S3 Structural alignment of BsPNP233 subunit
with homologous hexameric PNPs protomers. The regions
with the highest r.m.s.d. values are colored: BsPNP233 (green),
BaPNP (blue - PDB 1XE3/F), BcPNP (yellow - PDB 2AC7/B),
EcPNP (red - PDB 1ECP/A).
(TIF)
Table S1 Data collection and refinement statistics.
(DOC)
Table S2 Distances (A˚) between the ligand atoms and
interacting BsPNP233 atoms. Potential hydrogen bonds are
highlighted by grey boxes. In the case of crystal structures
containing more than one complex per asymmetric unit, only one
of them is shown in the table. For the ligand adenine a
representative structure of the preferential1 (BsPNP233-Ade
complex, chain A) and alternative¥ (form I, chain A) conforma-
tions are presented.
(DOC)
Table S3 In silico prediction of ligand binding affinity
using the rerank score function of MOLEGRO [75]. ¥ The
two values of BsPNP233-ACV complex correspond to the ACV1
Figure 8. Structural basis of distinct kinetic models for phosphate binding in hexameric PNPs. A. Structural superposition of BsPNP233-
sulfate open (green) and closed (pink) conformations with the BcAdoP-Ado complex (yellow, PDB code 3UAW, [52]). The cartoon representation
highlights the conformational differences observed in the main chain of the b9-a7 loop and the N-terminal portion of helix a7 in the three structures.
Dashed lines represent hydrogen bonds and follow the color code of their respective structures. B. The surface representation of BsPNP233 Phe220 in
the closed conformation (pink) and of the BcAdoP Thr91 evidence the steric hindrance imposed by the Thr91Cc2 atom to that Phe220 rotamer. C. The
surface representation of BsPNP233 Phe220 and Ser90 in the closed conformation shows that the Ser90 side chain allows the Phe220 side chain to
perform the conformational change needed for the closed conformation takes place.
doi:10.1371/journal.pone.0044282.g008
Structural Insights into Hexameric PNPs
PLOS ONE | www.plosone.org 9 September 2012 | Volume 7 | Issue 9 | e44282
and ACV2 alternative conformations, respectively. 1 HsPNP-ACV
(PDB CODE: 1PWY).
(DOC)
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